LGND Ligand Pharmaceuticals Incorporated

122.59
-2.27  -2%
Previous Close 124.86
Open 124.46
Price To Book 4.47
Market Cap 2506402444
Shares 20,445,407
Volume 245,871
Short Ratio
Av. Daily Volume 836,626

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

FDA approval announced March 19, 2018.
Brexanolone - SAGE-547 (202C)
Postpartum Depression - moderate
Phase 3 top-line data due 2H 2020.
Sparsentan - DUPLEX
Focal segmental glomerulosclerosis (FSGS)
Phase 2 additional NAFLD data to be presented at EASL April 11-14, 2019 with Phase 2b trial to be initiated 2H 2019.
VK2809
Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease
sNDA filing due 2Q 2019.
Baxdela
Community-acquired bacterial pneumonia (CABP)
Phase 3 data due 1H 2022.
Sparsentan
IgA nephropathy
Phase 2 interim positive data released March 4, 2019.
RPL554 DPI formulation
Maintenance treatment of COPD

Latest News

  1. Ligand to Receive Milestone and Royalties as Result of FDA Approval of Sage Therapeutics’ ZULRESSO™ (brexanolone) Injection
  2. Zacks.com featured highlights include: Catabasis, Ligand, Key, Carbonite and Second Sight
  3. Rising P/E an Overlooked Criterion: 5 Top Stocks
  4. Ligand Pharmaceuticals Inc (LGND) CEO John L Higgins Bought $285,725 of Shares
  5. LGND vs. ILMN: Which Stock Should Value Investors Buy Now?
  6. Zacks.com featured expert Kevin Matras highlights: Sallie Mae, United Continental, Celgene and Ligand Pharmaceuticals
  7. Ligand to Participate in Four Upcoming Investor Conferences
  8. Ligand Provides Highlights from Today’s Analyst Day Event
  9. 4 High Earnings Yield Stocks to Strengthen Your Portfolio
  10. Sermonix to Present at Boston Oncology Investor Conference on Potential for Lasofoxifene in Metastatic Breast Cancer Treatment
  11. Ligand (LGND) Down 9.1% Since Last Earnings Report: Can It Rebound?
  12. Investors Who Bought Ligand Pharmaceuticals Shares Five Years Ago Are Now Up 46%
  13. Here's Why Ligand Pharmaceuticals Is Having a Bad Day
  14. Ligand Sells Promacta Rights for $827M, Updates '19 View
  15. Ligand Sells Promacta Assets and Royalty for $827 Million
  16. Detailed Research: Economic Perspectives on Twenty-First Century Fox, Acadia Healthcare, Targa Resources, WellCare Health Plans, Ligand Pharmaceuticals, and Duke Energy — What Drives Growth in Today's Competitive Landscape
  17. Sermonix to Present Poster at ENDO 2019 on Lasofoxifene’s ‘Potent Anti-Tumor Activity’ in ESR1 Hormone-Resistant Breast Cancer
  18. Reminder: Ligand to Host Analyst Day on March 12th in New York City
  19. Biotech Stock Roundup: Regeneron Impresses in Q4, Gilead Slumps, MacroGenics Soars
  20. Edited Transcript of LGND earnings conference call or presentation 7-Feb-19 9:30pm GMT